Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting […]

The race to deliver safe, effective non-opioid pain therapeutics has never been more urgent - or more achievable. After decades of setbacks, the field is achieving long-awaited progress with recent regulatory approvals from Tonix and Vertex, strategic acquisitions from Eli Lilly, and late-stage successes validating the commercial potential of novel mechanisms. However, the clinical pathway […]

The 5th mRNA-Based Therapeutics Summit Europe is the leading European industry-focused forum dedicated to accelerating the safe, scalable, and clinically impactful development of messenger RNA (mRNA) medicines. Returning for its fifth year in Berlin from 27 - 29 January 2026, this essential meeting unites 170+ senior leaders across R&D, CMC (Chemistry, Manufacturing, and Controls), Regulatory […]

With global cases of AMD, DME, and glaucoma rapidly increasing, ophthalmic drug R&D is accelerating to meet urgent unmet needs. However, poor treatment adherence, invasive procedures, and adverse side effects continue to limit therapeutic success, highlighting the critical need for optimized delivery approaches. Recent developments, including Genentech’s Susvimo label expansion, advances in sustained-release and suprachoroidal delivery […]

The 6th Age-Related Disease Therapeutics Summit is the leading global meeting dedicated to advancing therapies that target the biology of aging and age-related diseases. Over three days, the summit brings together senior decision-makers from biopharma, biotech innovators, investors, and academic researchers to accelerate the development and commercialization of next-generation therapeutics. As the aging population grows, […]

2025 is proving to be a landmark year for RNAi. From Alnylam’s first approval in hemophilia to Novartis’ $1.2 billion acquisition of Avidity Biosciences and GSK diving into COPD with an $85 million siRNA licensing deal, the headlines haven’t stopped. RNAi is officially outgrowing its liver roots and entering a new era of therapeutic expansion. […]

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling. As the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies, the oncology landscape is transforming. Exciting modalities like ADCs, bispecifics, T-cell engagers demand smarter, more predictive […]

Alzheimer’s and Parkinson’s pipelines are rapidly expanding beyond amyloid and into next-generation mechanisms such as α-synuclein, neuroinflammation, and metabolic targets. Against the backdrop of a globally surging patient population, the urgency for more effective, disease-modifying interventions has never been greater. In its 14th year, the Alzheimer’s and Parkinson’s Drug Development Summit is committed to spotlighting […]

With Novartis committing $750M to ProFound Therapeutics to discover new cardiovascular candidates, and Illumina acquiring SomaLogic for $425 to expand its proteomic capabilities just this year alone, the increasing recognition of proteomics as a transformative force in drug discovery is unquestionable. Returning to Boston for its second year, the Proteomics-Based Drug Discovery Summit is the premier industry event […]

The past decade has transformed liquid biopsy, which was previously just an exciting concept, into a routine, commercially viable technology that is saving patients’ lives and transforming clinical trials. Uniting the field in San Diego February 3-5, 2026 for 3 days of data- and strategy-driven presentations and networking sessions, the 10th Liquid Biopsy for Precision […]

Across pharma, biotech, chemicals, FMCG, and beyond, laboratory leaders are facing the same challenge: how to turn the vision of a smart, digital lab into reality. From harmonising data and making it AI-ready to unlocking the true value of automation, the journey from concept to execution is complex - but critical. SmartLab Exchange Europe 2026 […]

The Longest Standing & Pre-Eminent European ADC Forum 16th World ADC London | 800+ Industry Attendees | 240+ Companies | 110+ Global Speakers With traditional ADCs now fulfilling their potential to reshape oncology care, the bioconjugate community is doubling down on differentiation to ensure the next generation delivers meaningful patient impact. Returning as the longest-standing […]

The Measuring Impact in Medical Affairs Summit is uniting Medical Affairs leaders from across pharma and biotech to define, benchmark, and standardize meaningful KPIs that capture the true value of Medical Affairs activities. As Medical Affairs cements its role as the strategic bridge between R&D and commercialization, the pressure to quantify and communicate impact has never been […]

As regulators and payers increasingly elevate the importance of RWE in submission and reimbursement requirements, the upcoming EHDS regulation marks a landmark move towards data sharing, and increasingly robust AI transforms big data analysis, it has never been more critical to harness RWE to uncover unmet needs, demonstrate treatment value beyond the clinical trial setting, […]

Now in its 8th year, LEAP HR: Life Sciences Europe is where the industry’s most ambitious HR leaders come together to find new solutions to their most pressing people challenges that they can immediately deploy to demonstrate meaningful business impact. Uncover the boldest strategies for driving talent agility, embedding AI and analytics, and building future-ready workforces - […]

Accelerate Licensing & Co-Development in Asia: Providing Pharma De-Risked Assets to Fuel Pipelines Faster, & Biotech Access to International Partnerships & Capital With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked […]